FDA approves Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer

The FDA has approved Pfizer's Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer, expanding the combination into an earlier treatment setting.
The approval authorises Talzenna (talazoparib) with Xtandi (enzalutamide) for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer whose tumours harbour homologous recombination repair gene mutations identified using an FDA-authorised test.
The decision was supported by the Phase III TALAPRO-3 study involving 599 patients and extends the combination's use beyond its previously authorised metastatic castration-resistant prostate cancer indication.
Field | Content |
Article Type | Approvals |
Regulatory Authority | U.S. Food and Drug Administration |
Regulatory Decision | New indication approval |
Approval Date | 26 October 2026 |
Company | Pfizer |
Approved Combination | Talzenna plus Xtandi |
Active Ingredients | Talazoparib; enzalutamide |
Drug Classes | PARP inhibitor; androgen receptor inhibitor |
Therapeutic Area | Oncology; prostate cancer |
Approved Indication | Metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations |
Patient Population | Adults with eligible HRR-mutated metastatic prostate cancer |
Biomarker | Homologous recombination repair gene mutations |
Biomarker Testing | FDA-authorised test |
Supporting Clinical Study | Phase III TALAPRO-3 |
Study Enrollment | 599 patients |
Efficacy Results | Specific efficacy estimates not provided in supplied summary |
Previous Approved Setting | Metastatic castration-resistant prostate cancer |
New Treatment Setting | Earlier metastatic androgen pathway modulation-naïve or -sensitive disease |
Geography | United States |
What Happened | The FDA approved talazoparib with enzalutamide for adults with HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. |
Why It Matters | The approval expands access to a biomarker-directed PARP inhibitor combination earlier in the metastatic prostate cancer treatment pathway. |
Clinical Evidence | The Phase III TALAPRO-3 study enrolled 599 patients; detailed efficacy outcomes were not included in the supplied summary. |
Key Takeaway | Talzenna plus Xtandi now has an additional US indication for selected HRR-mutated metastatic prostate cancers beyond the castration-resistant setting. |
What to Watch | Updated prescribing information, biomarker testing uptake, clinical guideline integration, reimbursement and real-world outcomes. |
Primary Source | U.S. Food and Drug Administration |
Primary Source URL | https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive |
Relevant Date | 26 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

댓글